COVID-19 Pandemic Public Health Research

Initial results from COVID-19 vaccine trial in children 5 to 11 years old

Today Pfizer / BioNTech SE announced positive topline results from COVID-19 vaccine trial in children 5 to 11 years old via press release (still waiting for full report and data).

Highlights given in Press Release of Phase 2/3 trial (link in below):

  • a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years old using a two-dose regimen of 10 µg administered 21 days apart (smaller dose than the 30 µg dose used for 12 years old+)
  • antibody responses seen via given 10 µg doses were comparable to those recorded in previous Pfizer-BioNTech study in people 16 to 25 years old immunized with 30 µg doses

Since July in United States, the pediatric cases of COVID-19 have risen by about 240 percent.

Still a ways to go as full data and reports need to be released along with passing the safety mechanisms via FDA and the Centers for Disease Control and Prevention panels still need to review and approve, at least in United States, if and when these vaccines could be used.

📸 credit & caption: Mike Segar | Reuters – 12 year-old Justing Concepcion receives a dose of the Pfizer-BioNTech vaccine for the coronavirus disease (COVID-19) from registered nurse Angela Nyarko, during a vaccination event for local adolescents and adults outside the Bronx Writing Academy school in the Bronx, New York.

Further information about results via Press Release:

Leave a Reply

Your email address will not be published. Required fields are marked *